Laboratorio de Energía Solar Termoeléctrica

Knight Therapeutics Inc. places No. 22 on The Globe and Mail's fourth-annual ranking of Canada's Top Growing Companies

Retrieved on: 
Friday, September 23, 2022

MONTREAL, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (Knight or the Company) is pleased to announce it placed No.

Key Points: 
  • MONTREAL, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (Knight or the Company) is pleased to announce it placed No.
  • 22 on the 2022 Report on Business ranking of Canadas Top Growing Companies.
  • Canadas Top Growing Companies ranks Canadian companies on three-year revenue growth.
  • Canadas Top Growing Companies is an editorial ranking that was launched in 2019.

Knight to Present at the Canaccord Genuity 42nd Annual Growth Conference

Retrieved on: 
Thursday, August 4, 2022

MONTREAL, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 11:00 am ET.

Key Points: 
  • MONTREAL, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 11:00 am ET.
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on www.sedar.com .

Notice of Knight Therapeutics' Second Quarter 2022 Results Conference Call

Retrieved on: 
Thursday, August 4, 2022

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.

Key Points: 
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on www.sedar.com .
  • Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information or future events, except as required by law.

Knight Announces Normal Course Issuer Bid

Retrieved on: 
Tuesday, July 12, 2022

MONTREAL, July 12, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "), a leading pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a Normal Course Issuer Bid ("NCIB").

Key Points: 
  • MONTREAL, July 12, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "), a leading pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a Normal Course Issuer Bid ("NCIB").
  • Knight also entered into an automatic share purchase plan with a broker in order to facilitate purchases of its common shares under the NCIB.
  • The price that Knight will pay for Common Shares in open market transactions will be the market price at the time of purchase.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com
    This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries.

Knight to Present at the 2022 BIO International Convention in San Diego

Retrieved on: 
Tuesday, June 7, 2022

MONTREAL, June 07, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at the 2022 BIO International Convention on Tuesday, June 14, 2022 at 2:45 pm Pacific Time.

Key Points: 
  • MONTREAL, June 07, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at the 2022 BIO International Convention on Tuesday, June 14, 2022 at 2:45 pm Pacific Time.
  • The annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the worlds largest industry gathering and brings together thousands of global biotechnology and biopharmaceutical leaders.
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .

DGAP-News: SYNLAB AG: SYNLAB achieves record results in 2021 and exceeds all targets set at the IPO

Retrieved on: 
Wednesday, March 16, 2022

The net revenue contribution from COVID-19 was approximately 1.56 billion [3] , with SYNLAB performing 29.7 million PCR and 5.6 million non-PCR tests during the year 2021.

Key Points: 
  • The net revenue contribution from COVID-19 was approximately 1.56 billion [3] , with SYNLAB performing 29.7 million PCR and 5.6 million non-PCR tests during the year 2021.
  • Accelerate organic growth: As part of its retail initiative, SYNLAB accelerated the pace of blood collection point openings (>150 in 2021).
  • In 2021, SYNLAB completed 18 acquisitions for a total revenue contribution of 143 million [10] , representing 5.4% revenue growth.
  • At the time of the successful IPO, SYNLAB set a number of financial targets based on the Group's growth strategy.